Septerna, Inc. is advancing innovative programs in GPCR drug discovery with a focus on oral small molecules.
The company's Native Complex Platform™ aims to unlock the full potential of GPCR therapies through structure-based drug design.
Septerna's portfolio strategy targets validated GPCR targets with significant market opportunities.
PTH1R Agonist Program Progress
Phase 1 clinical trial for SEP-479 planned for the first half of 2026, pending preclinical activities and regulatory approvals.
SEP-631 Potential
SEP-631 offers a convenient oral treatment for patients with CSU and mast cell-driven diseases, with initial clinical data expected in the first half of 2026.
Collaboration with Novo Nordisk
Joint discovery of potential oral small molecule therapies for obesity and cardiometabolic diseases, with projected milestones and royalties.
- Septerna's focus on advancing PTH1R Agonist and SEP-631 programs has the potential to address significant unmet medical needs in various diseases.
- The collaboration with Novo Nordisk enhances the company's position in developing therapies for metabolic diseases.
Septerna's pioneering approach in GPCR drug discovery, supported by innovative platforms and strategic collaborations, positions the company for future growth and value creation in the pharmaceutical industry.